Literature DB >> 31207241

CRISPR/Cas9-based Knockout Strategy Elucidates Components Essential for Type 1 Interferon Signaling in Human HeLa Cells.

Victoria Urin1, Maya Shemesh1, Gideon Schreiber2.   

Abstract

Type I interferons (IFNs) have a central role in innate and adaptive immunities, proliferation, and cancer surveillance. How IFN binding to its specific receptor, the IFN α and β receptor (IFNAR), can drive such variety of processes is an open question. Here, to systematically and thoroughly investigate the molecular mechanism of IFN signaling, we used a CRISPR/Cas9-based approach in a human cell line (HeLa) to generate knockouts (KOs) of the genes participating in the type 1 IFN signaling cascade. We show that both IFNAR chains (IFNAR1 and IFNAR2) are absolutely required for any IFN-induced signaling. Deletion of either signal transducer and activator of transcription 1 (STAT1) or STAT2 had only a partial effect on IFN-induced antiviral activity or gene induction. However, the deletion of both genes completely abrogated any IFN-induced activity. So did a double STAT2-IFN regulatory factor 1 (IRF1) KO and, to a large extent, a STAT1 KO together with IRF9 knockdown. KO of any of the STATs had no effect on the phosphorylation of other STATs, indicating that they bound IFNAR independently. STAT3 and STAT6 phosphorylations were fully induced by type 1 IFN in the STAT1-STAT2 KO, but did not promote gene induction. Moreover, STAT3 KO did not affect type 1 IFN-induced gene or protein expression. Type 1 IFN also did not activate p38, AKT, or ERK kinase. We conclude that type 1 IFN-induced activities in HeLa cells are mediated by STAT1/STAT2/IRF9, STAT1/STAT1, or STAT2/IRF9 complexes and do not require alternative pathways.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  antiviral activity; gene regulation; protein phosphorylation; signal transduction; type I interferon

Mesh:

Substances:

Year:  2019        PMID: 31207241     DOI: 10.1016/j.jmb.2019.06.007

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  9 in total

1.  Type I Interferon acts as a major barrier to the establishment of infectious bursal disease virus (IBDV) persistent infections.

Authors:  Laura Broto; Nicolás Romero; Fernando Méndez; Elisabet Diaz-Beneitez; Oscar Candelas-Rivera; Daniel Fuentes; Liliana L Cubas-Gaona; Céline Courtillon; Nicolas Eterradossi; Sébastien M Soubies; Juan R Rodríguez; Dolores Rodríguez; José F Rodríguez
Journal:  J Virol       Date:  2020-12-16       Impact factor: 5.103

Review 2.  Type I Interferon (IFN)-Regulated Activation of Canonical and Non-Canonical Signaling Pathways.

Authors:  Candice Mazewski; Ricardo E Perez; Eleanor N Fish; Leonidas C Platanias
Journal:  Front Immunol       Date:  2020-11-23       Impact factor: 7.561

Review 3.  Shared and Unique Features of Human Interferon-Beta and Interferon-Alpha Subtypes.

Authors:  Megen C Wittling; Shannon R Cahalan; Eric A Levenson; Ronald L Rabin
Journal:  Front Immunol       Date:  2021-01-19       Impact factor: 7.561

4.  A host cell long noncoding RNA NR_033736 regulates type I interferon-mediated gene transcription and modulates intestinal epithelial anti-Cryptosporidium defense.

Authors:  Juan Li; Kehua Jin; Min Li; Nicholas W Mathy; Ai-Yu Gong; Silu Deng; Gislaine A Martins; Mingfei Sun; Juliane K Strauss-Soukup; Xian-Ming Chen
Journal:  PLoS Pathog       Date:  2021-01-22       Impact factor: 6.823

5.  Polyamine Analog Diethylnorspermidine Restricts Coxsackievirus B3 and Is Overcome by 2A Protease Mutation In Vitro.

Authors:  Bridget M Hulsebosch; Bryan C Mounce
Journal:  Viruses       Date:  2021-02-16       Impact factor: 5.048

6.  Synthetic mimetics assigned a major role to IFNAR2 in type I interferon signaling.

Authors:  Nele Zoellner; Noémi Coesfeld; Frederik Henry De Vos; Jennifer Denter; Haifeng C Xu; Elena Zimmer; Birgit Knebel; Hadi Al-Hasani; Sofie Mossner; Philipp A Lang; Doreen M Floss; Jürgen Scheller
Journal:  Front Microbiol       Date:  2022-09-02       Impact factor: 6.064

7.  Progesterone receptor promotes degradation of STAT2 to inhibit the interferon response in breast cancer.

Authors:  Katherine R Walter; Justin M Balko; Christy R Hagan
Journal:  Oncoimmunology       Date:  2020-04-30       Impact factor: 8.110

Review 8.  The Role of Type I Interferons in the Pathogenesis and Treatment of COVID-19.

Authors:  Gideon Schreiber
Journal:  Front Immunol       Date:  2020-09-30       Impact factor: 7.561

9.  Determinants of Ligand Specificity and Functional Plasticity in Type I Interferon Signaling.

Authors:  Duncan Kirby; Baljyot Parmar; Sepehr Fathi; Sagar Marwah; Chitra R Nayak; Vera Cherepanov; Sonya MacParland; Jordan J Feld; Grégoire Altan-Bonnet; Anton Zilman
Journal:  Front Immunol       Date:  2021-10-07       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.